- Home
- IBG vs SXTP Comparison
IBG vs SXTP Comparison
Compare IBG & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBG | SXTP |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | Australia | United States |
| Employees | 9 | 3 |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5M | 2.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IBG | SXTP |
|---|---|---|
| Price | $1.18 | $1.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.60 |
| AVG Volume (30 Days) | 710.6K | ★ 2.4M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $146.28 |
| Revenue Next Year | N/A | $24.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.30 | $0.34 |
| 52 Week High | $6.50 | $8.62 |
Technical Indicators
Market Signals| Indicator | IBG | SXTP |
|---|---|---|
| Relative Strength Index (RSI) | 35.47 | 34.27 |
| Support Level | $0.55 | $1.19 |
| Resistance Level | $1.61 | $1.49 |
| Average True Range (ATR) | 0.46 | 0.41 |
| MACD | -0.22 | -0.09 |
| Stochastic Oscillator | 5.49 | 3.32 |
Price Performance
Historical ComparisonAbout IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.